Comparing Low-Intensity and Medium-Intensity Continuous Kidney Replacement Therapy in Critically Ill Adults

What this Trial Is About

Researchers are evaluating whether low treatment intensity 12 mLkghr or medium treatment intensity 25 mLkghr continuous kidney replacement therapy is more effective and safer for critically ill patients with acute kidney injury. This interventional clinical trial is sponsored by Jikei University School of Medicine and uses a randomized, parallel study design to compare these two dosing strategies in an intensive care setting. The study is conducted to understand the best approach to continuous renal replacement therapy for patients requiring this treatment. Participants are randomly assigned to receive either low-intensity or medium-intensity continuous hemodialysis andor hemofiltration, delivered through dialysate fluid and filtration replacement fluid. The study compares these two dosing levels, with interventions administered continuously while patients are in intensive care units. The trial includes phases 2 and 3 and is planned to complete by June 2030. During the study, participants are monitored for outcomes such as death and duration of kidney replacement therapy over 28 days or until hospital discharge, whichever comes first. Additional evaluations include ICU and hospital mortality, dialysis dependence, vasopressor-free days, ventilator-free days, serum creatinine levels, and urine output at kidney replacement therapy end. The total participation timeline extends up to hospital discharge or 90 days, with assessments performed at multiple time points to measure treatment effects and safety.

Low-intensity Versus Medium-intensity Continuous Kidney Replacement Therapy for Critically Ill Patients